The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …

Personalized immunotherapy targeting tumor-specific antigens (TSAs) could generate
efficient and safe antitumor immune response without damaging normal tissues. Although …

Genetically engineered mouse models (GEMM s) have contributed significantly to the field of
cancer research. In contrast to cancer cell inoculation models, GEMM s develop de novo …

Recently, there has been an increasing interest in the development and characterization of
patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly …

Patient-derived xenograft (PDX) models are created by engraftment of patient tumor tissues
into immunocompetent mice. Since a PDX model retains the characteristics of the primary …

Establishing an appropriate preclinical model is crucial for translational cancer research.
The most common way that has been adopted by far is grafting cancer cell lines, derived …

Progress in oncology drug development has been hampered by a lack of preclinical models
that reliably predict clinical activity of novel compounds in cancer patients. In an effort to …

Tumor graft models (also known as patient-derived xenografts or PDX) are based on the
transfer of primary tumors directly from the patient into an immunodeficient mouse. Because …

More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient
efficacy. We hypothesized that adequately powered trials of patient-derived xenografts …